[Take-home messages from the COPD 2021 biennial of the French Society of Respiratory Diseases. Understanding to so as to better innovate]

J Ancel; M Guecamburu; V Marques Da Silva; P Schilfarth; L Boyer; C Pilette; C Martin; P Devillier; P Berger; M Zysman; O Le Rouzic; J Gonzalez-Bermejo; B Degano; P-R Burgel; E Ahmed; N Roche; G Deslee

doi:10.1016/j.rmr.2022.03.013

[Take-home messages from the COPD 2021 biennial of the French Society of Respiratory Diseases. Understanding to so as to better innovate]

Rev Mal Respir. 2022 May;39(5):427-441. doi: 10.1016/j.rmr.2022.03.013. Epub 2022 May 12.

[Article in French]

Authors

J Ancel¹, M Guecamburu², V Marques Da Silva³, P Schilfarth⁴, L Boyer⁵, C Pilette⁶, C Martin⁷, P Devillier⁸, P Berger⁹, M Zysman⁴, O Le Rouzic¹⁰, J Gonzalez-Bermejo¹¹, B Degano¹², P-R Burgel⁷, E Ahmed¹³, N Roche⁷, G Deslee¹⁴

Affiliations

¹ Inserm UMRS-1250, service de pneumologie, université Reims Champagne Ardenne, hôpital Maison Blanche, Reims, France.
² Service des maladies respiratoires, hôpital du Haut-Lévêque, CHU de Bordeaux, Bordeaux, France.
³ Inserm U955, FHU SENEC, université Paris-Est Créteil, institut Mondor de recherche biomédicale, équipe GEIC2O, Créteil, France.
⁴ Service des maladies respiratoires, hôpital du Haut-Lévêque, CHU de Bordeaux, Bordeaux, France; Inserm U1045, centre de recherche cardio-thoracique de Bordeaux, Pessac, France.
⁵ Département de physiologie-explorations fonctionnelles, université Paris-Est, hôpital Henri-Mondor, AP-HP, UMR S955, FHU SENEC, UPEC, Créteil, France.
⁶ Département de pneumologie, université catholique de Louvain, cliniques universitaires Saint-Luc et institut de recherche expérimentale et clinique, Bruxelles, Belgique.
⁷ Inserm U1016, service de pneumologie, AP-HP Paris, hôpital Cochin et institut Cochin, université de Paris, Paris, France.
⁸ Département des maladies respiratoires, unité de recherche en pharmacologie respiratoire, VIM Suresnes (UMR 0892, université Paris-Saclay), hôpital Foch, Suresnes, France.
⁹ Service d'exploration fonctionnelle respiratoire, département de pharmacologie, centre de recherche cardiothoracique, U1045, CIC 1401, Pessac, France.
¹⁰ Inserm, CIIL Center for infection and immunity of Lille, université de Lille, CHU de Lille, pneumologie et immuno-allergologie, Institut Pasteur de Lille, U1019 - UMR9017, Lille, France.
¹¹ Inserm, UMRS115 neurophysiologie respiratoire expérimentale et clinique, service de pneumologie, médecine intensive et réanimation (département R3S), Sorbonne université, groupe hospitalier universitaire AP-HP, Sorbonne Université, site Pitié-Salpêtrière, Paris, France.
¹² Inserm 1042, service de pneumologie physiologie, CHU de Grenoble, Grenoble, France.
¹³ Département des maladies respiratoires, IRMB, université de Montpellier, CHU de Montpellier, Montpellier, France.
¹⁴ Inserm UMRS-1250, service de pneumologie, université Reims Champagne Ardenne, hôpital Maison Blanche, Reims, France. Electronic address: gdeslee@chu-reims.fr.

PMID: 35568574
DOI: 10.1016/j.rmr.2022.03.013

Abstract

Introduction: The first COPD biennial organized by the French Society of Respiratory Diseases (SPLF) took place on 17 December 2021.

State of the art: The objective of the biennial was to discuss current knowledge regarding COPD pathophysiology, current treatments, research development, and future therapeutic approaches.

Perspectives: The different lecturers laid emphasis on the complexity of pathophysiologic mechanisms including bronchial, bronchiolar and parenchymal alterations, and also dwelt on the role of microbiota composition in COPD pathenogenesis. They pointed out that addition to inhaled treatments, ventilatory support and endoscopic approaches have been increasingly optimized. The development of new therapeutic pathways such as biotherapy and cell therapy (stem cells…) call for further exploration.

Conclusions: The dynamism of COPD research was repeatedly underlined, and needs to be further reinforced, the objective being to "understand so as to better innovate" so as to develop effective new strategies for treatment and management of COPD.

Keywords: Biological Therapy; Biothérapie; Broncho-pneumopathie chronique obstructive; Chronic Obstructive Pulmonary Disease; Microbiota; Microbiote; Médecine de précision; Physiopathologie; Physiopathology; Precision Medicine.

Publication types

Review

MeSH terms

Humans
Microbiota*
Pulmonary Disease, Chronic Obstructive* / epidemiology
Pulmonary Disease, Chronic Obstructive* / therapy
Respiration Disorders*